Medication overuse headache: a critical review of end points in recent follow-up studies

Size: px
Start display at page:

Download "Medication overuse headache: a critical review of end points in recent follow-up studies"

Transcription

1 J Headache Pain (2010) 11: DOI /s REVIEW ARTICLE Medication overuse headache: a critical review of end points in recent follow-up studies Knut Hagen Rigmor Jensen Magne Geir Bøe Lars Jacob Stovner Received: 22 February 2010 / Accepted: 25 April 2010 / Published online: 16 May 2010 Springer-Verlag 2010 Abstract No guidelines for performing and presenting the results of studies on patients with medication overuse headache (MOH) exist. The aim of this study was to review long-term outcome measures in follow-up studies published in 2006 or later. We included MOH studies with [6 months duration presenting a minimum of one predefined end point. In total, nine studies were identified. The 1,589 MOH patients (22% men) had an overall mean frequency of 25.3 headache days/month at baseline. Headache days/month at the end of follow-up was reported in six studies (mean 13.8 days/month). The decrease was more pronounced for studies including patients with migraine only (-14.6 days/month) compared to studies with the original diagnoses of migraine and tension-type headache (-9.2 days/month). Six studies reported relapse rate (mean of 26%) and/or responder rate (mean of 28%). Medication days/month and change in headache index at the end of follow-up were reported in only one and two of nine K. Hagen L. J. Stovner Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway K. Hagen (&) L. J. Stovner Section of Neurology, Department of Neurology, Norwegian National Headache Centre, St. Olavs Hospital, 7006 Trondheim, Norway knut.hagen@ntnu.no R. Jensen Department of Neurology, Danish Headache Centre, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark M. G. Bøe Department of Neurology, Sørlandet Hospital, Kristiansand, Norway studies, respectively. The present review demonstrated a lack of uniform end points used in recently published follow-up studies. Guidelines for presenting follow-up data on MOH are needed and we propose end points such as headache days/month, medication days/month, relapse rate and responder rate defined as C50% reduction of headache frequency and/or headache index from baseline. Keywords Medication overuse headache Follow-up Outcome parameters Relapse rate Responders Introduction Worldwide, approximately 1 2% of the adult general population suffers from chronic headache (C15 days/ month) combined with medication overuse [1 6]. The optimal method of treating the many patients with medication overuse headache (MOH) is still controversial, mainly due to lack of placebo-controlled, double-blind, randomized clinical trials [7]. No established consensus for treatment strategies exists for patient with MOH. As a consequence, the therapeutic strategies for the acute phase of detoxification and the use of preventive treatment differ widely between studies [8]. Most previous follow-up studies of patients with MOH are case series and non-randomized studies, which are difficult to interpret. The lack of high-quality studies makes it difficult to draw firm conclusions regarding the management of MOH [8]. During the last two decades, several guidelines for controlled treatment trials for patients with migraine and tension-type headache have been published [9 11], also emphasizing the need of uniform end points. However, no guidelines on performing and presenting the result of studies on MOH patients exist. Due to the lack of

2 374 J Headache Pain (2010) 11: guidelines, it may be of relevance to review the type of end points published in recent follow-up studies of MOH patients. The aim of this study was to analyze and summarize the long-term outcome measures of MOH patients included in follow-up studies published in 2006 or later. Methods Follow-up studies of patients with MOH published in English were identified through PubMed by searching for relevant publications between January 2006 and December We used the search terms medication overuse headache combined with follow-up. References listed in relevant publications were also examined. All studies were first screened for various aspects of methodology and design, and type of content, to select studies of interest for our purpose. Studies on MOH patients who underwent one type of intervention were labeled case series, whereas studies including at least two types of interventions were labeled controlled studies. We included studies fulfilling the following four minimum criteria: (1) published in 2006 or later. Recently published studies were preferred because the majority of these studies included patients fulfilling the Headache Classification Committee of the International Headache Society from 2004 (ICDH-2) or later modified versions [12 14]; (2) [6 months duration of follow-up; (3) at least two of the following characteristics mentioned explicitly at baseline: primary headache type, headache days/month and/or medication days/month; (4) at least one of the following end points mentioned explicitly at follow-up: headache days/month, reduction of headache frequency from baseline, medication days/month, reduction of medication days from baseline, responder rate defined as the proportion of individuals with C50% reduction of headache frequency from baseline [10], or relapse rate defined as the proportion of individuals with the diagnosis of MOH at the end of follow-up among subjects with successful withdrawal. In this context patients with successful withdrawal were defined as those not overusing medication after the withdrawal period, regardless of whether they experienced reduction of headache frequency or not. Statistics Mean values of the total group of participants were presented if available. If mean values of, for e.g., three subgroups were presented, mean values for the total group were calculated by the following formula: (days/month 9 number of participants in group A? days/month 9 number of participants in group B? days/month 9 number of participants in group C) divided by total number of participants in group A, B and C. Mean reduction of headache days/month (as percentage) from baseline was also calculated. Results Initially, 33 studies were identified by the PubMed search. This was reduced to 28 unique studies after removing multiple publications based on the same patients [15 19]. Overall, nine follow-up studies, all clinic-based, fulfilled the four criteria of the present review. To optimize comparisons between studies, 12 months follow-up data were preferred in one study, although 3- and 5-year follow-up data were also available [19]. Five studies included only MOH patients who had had migraine before developing MOH, whereas the remaining four studies also included patient who had had TTH (Table 1) [15, 20 27]. Four follow-up studies were case series without controls [20 22, 26]: one retrospective [20] and three prospective studies [21, 22, 26]. The remaining five studies were categorized as controlled studies with (n = 3) [23 25] or without confirmed randomization (n = 2) [15, 27] (Table 1). Headache diary was used in five studies during the follow-up [20, 22 25] and most likely used, although not explicitly stated, in two additional studies [15, 27]. In eight studies (Table 1) [15, 21 27], 12-month follow-up data were available. Two Italian studies used the criteria for chronic migraine proposed by Silberstein and Lipton in 2000 [15, 22], whereas the remaining patients fulfilled the Headache Classification Committee of the International Headache Society from 2004 (ICDH-2) [20, 23, 25, 27] or later modified versions [21, 24, 26]. Although the specific treatment protocol differed widely between the nine studies, all studies included abrupt withdrawal as a part of the protocol (Table 2). Prophylactic treatment was initiated during the first week in the majority of studies (range 1 90 days) (Table 2). The 1,589 MOH patients (22% men) included in the nine different studies had an overall mean of 25.3 headache days per month (range ) at baseline. Headache days at the end of follow-up were reported in six studies (n = 582, mean follow-up duration 11.3 months, mean days/month = 45% decrease from baseline) [15, 20, 22, 24, 25, 27]. The mean decrease was more pronounced for the studies including patients with migraine only (n = 290, mean follow-up duration 12 months, days/month = 56% decrease from baseline) [15, 22, 27] than among those with migraine and TTH (n = 29,

3 J Headache Pain (2010) 11: Table 1 Study characteristics at baseline Study, reference Country Number included (% men) Age group (range) TTH included Duration (months) Design 2006 [20] Denmark 337 (27) Yes 8 Retrospective case series 2007 [21] Serbia 240 (24) Yes 12 Case series 2007 [22] Italy 106 (18) No 12 f Case series 2008 [23] Italy 118 (16) No 12 Randomized controlled a 2009 [24] Norway 61 (39) Yes 12 Randomized controlled b 2009 [25] Norway 100 (26) Yes 12 Double-blind RCT c? randomized controlled c 2009 [26] Italy 215 (19) No 12 Case series 2009 [27] Italy 93 ( ) No 12 Controlled d 2009 [15] Italy 260 ( ) No 12 Controlled e a Three groups: advice alone versus structured detoxification as in- or outpatient b Three groups: prophylactic treatment from the start without detoxification versus standard outpatient detoxification program without prophylactic treatment from the start versus no specific treatment (controls) c Two groups: placebo-controlled, double-blind randomized controlled trial (RCT) evaluating efficacy of prednisolone on withdrawal headache followed by an controlled design evaluating long-term outcome of patients treated by neurologist versus GP d Two groups; randomization not stated: behavioral plus pharmacological treatment versus pharmacological treatment only e Two groups, randomization not stated: inpatient versus day-hospital withdrawal treatment f Data on 3 and 5 years follow-up also available Table 2 Initial treatment strategies Study, reference Abrupt withdrawal? In- or outpatient Days at hospital Infusion therapy? Onset of preventive drugs 2006 [20] Yes Outpatient 0 No After 2 months 2007 [21] Yes In- or outpatient 8 Yes During the first weeks? b 2007 [22] Yes Inpatient 10 Yes Day [23] Yes Inpatient 8 Yes Day [24] Yes a Outpatient 0 No Day 1 or after 3 months 2009 [25] Yes Inpatient 3 No After 1 months 2009 [26] Yes Inpatient 10 Yes Day 4 or [27] Yes Day patient 5 Yes Day 5? b 2009 [15] Yes In- or day patient 7 Yes Day 6 a Abrupt withdrawal in one out of three groups b Incomplete information mean follow-up duration 10.7 months, -9.2 days/month = 36% decrease from baseline) [20, 24, 25]. The response rate and relapse rate were reported in only three [20, 24, 25] and four studies [21, 23, 25, 26], respectively, with a mean of 28 and 26% (Table 3). Medication days/month at the end of follow-up was reported in one study only [24], whereas two studies revealed information about change in the headache index at follow-up compared to baseline (data not given) [24, 25]. Discussion Study design and treatment strategy differ widely between the studies, and direct comparisons should be done with caution. However, in a recent review it was suggested that differences in withdrawal therapy strategy seem to have no major impact on long-term outcome [8]. If true, an overall 45% reduction in headache days and a 28% response rate during 1 year should be expected for the group of MOH patients in an open-labeled setting. However, the tendency of remission or worsening over time must be taken into account since these factors may overestimate the effect of treatment [28]. It should be emphasized that the lack of control group in all studies (except one) increases the risk that these results may be explained, at least in part, by the natural history or regression from the mean. These flaws may be avoided in randomized, double-blind, placebocontrolled studies. In one placebo-controlled study evaluating the efficacy of topiramate without withdrawal, a more

4 376 J Headache Pain (2010) 11: Table 3 End points used in nine follow-up studies Study, reference Number of dropouts (%) Headache days/ month baseline Duration of follow-up (months) Headache days/month Follow-up Medication days/ month baseline Medication days/ month follow-up Response rate a Number (%) Relapse rate Number (%) 2006 [20] 162/337 (48) e 67/337 b (20) 2007 [21] /240 (39.6) 2007 [22] 22/106 (21) [23] 37/118 (31) /83 (20.5) 2009 [24] 5/61 (8) b 17.1 e /41 c (34) 2009 [25] 20/100 (20) e 27/93 d (29) 16/80 (20) 2009 [26] 43/215 (20) /172 (22) 2009 [27] 36/93 (39) [15] 111/260 (43) Number Mean a Calculation of response rate (proportion of individuals with C50% reduction in headache frequency from baseline) differ between the three studies with respect to (a) number of participants included in the analysis and (b) time interval before evaluation b Analysis of 337 participants (all included) evaluated after a mean of 8 months c Analysis of 41 individuals evaluated after 12 months (20 controls excluded because of 5 months follow-up duration) d Analysis of 93 individuals evaluated 3 months after withdrawal e TTH patients included moderate decrease in headache days/month (approximately 25%) was found among MOH patients with chronic migraine [29]. The most important finding in the present review was a lack of uniform end points used in the nine follow-up studies. Headache days/month was the most commonly presented, followed by relapse rate and/or responder rate. Surprisingly, only two studies explicitly reported medication days/month at baseline [24, 26] and only one study did so at the end of follow-up [24], although this was crucial when considering the diagnosis of MOH and relapse rate. Although not clearly stated, one may assume that most studies had collected information about medication days/month at baseline according to MOH diagnosis based on ICDH-2 or later modified versions. Less informative than medication days/ month is the total number of medication doses consumed per month that was reported in four studies [15, 22, 23, 27]. The definition of responders varied between studies. In the study by Rossi et al. [23], responders were defined as those who had headache\15 days per month and intake of symptomatic medication \10 days/month 2 month after withdrawal treatment. However, using this definition (although it fulfills the ICDH-2 criteria), patients may be defined as responders even with a minor reduction in headache and intake of medication. In our opinion defining a responder as a patient with C50% reduction of headache frequency from baseline is more informative, although other definitions, e.g., C25% reduction of headache frequency from baseline, can be clinically meaningful for MOH patients [10]. Furthermore, for MOH patients headache index rather than headache days may more correctly reflect the total suffering [11]. Two studies had included such data based on frequency, duration and intensity [24] or frequency and intensity (named mean headache in the publication) [25] recorded in headache diaries. One may still discuss what the optimal definition of a responder is, but we would favor studies on MOH treatment that aim at C50% reduction in headache index from baseline. This was used as a secondary end point in one study [25]. In accordance, headache index as a primary efficacy measure has been proposed in the revised version of the guidelines for controlled trials of prophylactic drugs in chronic tensiontype headache [11]. However, for headache frequency one should acknowledge that less ambitious definition of end points, e.g., those with C25% reduction of headache index from baseline, can be clinically meaningful [10]. In one out of the four studies reporting relapse rates [21, 23, 25, 26], the calculation was restricted to individuals who had an improvement of headache at follow-up after 2 months [23]. However, in the study by Bøe et al. [25], a much lower relapse rate at 12 months follow-up was found among individuals with C50% improvement score at 3 months follow-up than among those without such improvement (4 vs. 28%). Thus, a higher relapse rate may be expected if individuals with no or some improvement of headache frequency after successful withdrawal are included in the analysis. The review demonstrated a lack of uniform end points in recently published follow-up studies of patient with MOH.

5 J Headache Pain (2010) 11: If possible, the evaluation of long-term outcome of patient with MOH should be based on headache diary information preferentially including data on headache days/month, headache intensity and medication days/month. We recommend that at the end of follow-up, minimum headache days/month and medication days/month are included, since these end points are needed to calculate relapse rate. In addition, we recommend that headache intensity and attack duration are included and that the responder rate is defined as C50% reduction of headache frequency and/or headache index from baseline. However, including end points such as C25% reduction of headache frequency and/or headache index may add useful information to the final selection of end points that should be preferred in the future. There is a need for increasing awareness of methodological issues in clinical follow-up studies for MOH. Guidelines for MOH studies including use of end points are needed. Conflict of interest References None. 1. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J (2004) Analgesic overuse among subjects with headache, neck and low-back pain. Neurology 62: Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ (2001) Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 21: Wang SJ, Fuh JL, Liu CY, Hsu LC, Wang PN, Liu HC (2000) Chronic daily headache in Chinese elderly. Prevalence, risk factors, and biannual follow-up. Neurology 54: Castillo J, Muñoz P, Guitera V, Pascual J (1999) Epidemiology of chronic daily headache in the general population. Headache 39: Colás R, Muñoz P, Temprano R, Gómez C, Pascual J (2004) Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 62: Aaseth K, Grande RB, Kværner KJ, Gulbrandsen P, Lundqvist C, Russell MB (2008) Prevalence of secondary chronic headaches in a population-based sample of year-old persons. The Akerhus study of chronic headache. Cephalalgia 28: Dodick DW (2006) Clinical practice. Chronic daily headache. N Engl J Med 354: Rossi P, Jensen J, Nappi G, Allena M (2009) The COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain 10: International Headache Society Committee on Clinical Trials in Migraine (1991) Guidelines for controlled trials of drugs in migraine, 1st edn. Cephalalgia 11: Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ (2008) Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28: Bendtsen L, Bigal ME, Cerbo R, Diener HC, Holroyd K, Lampl C, Mitsikostas DD, Steiner TJ, Tfelt-Hansen P (2009) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia [Epub ahead of print] 12. Headache Classification Committee of International Headache Society (2004) The international classification of headache disorders. 2nd ed. Cephalalgia 24(Suppl 1): Silberstein S, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez M, Lance LW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TS, on behalf of the International Headache Society (2005) The International Classification of Headache Disorders, 2nd Edition (ICHD-II) revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 25: Olesen J, Bousser MG, Diener HC, Dodck D, First M, Goadsby PJ, Göbel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silbertstein SD, Steiner TJ, Headache Classification Committee (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26: Usai S, Grazzi L, D Amico D, Andrasik F, Bussone G (2009) Psychological variables chronic migraine with medication overuse before and after inpatient withdrawal: results at 1-year follow-up. Neurol Sci 30:S125 S Usai S, Grazzi L, D Amico D, Andrasik F, Bussone G (2008) Reduction in the impact of chronic migraine with medication overuse after day-hospital withdrawal therapy. Neurol Sci 29:S176 S Ghiotto N, Sances G, Galli F, Tassorelli C, Guaschino Sandrini G, Nappi G (2009) Medication overuse headache and applicability of the ICDH-II diagnostic criteria: 1 year follow-up study (care I protocol). Cephalalgia 29: Bøe MG, Salvesen R, Mygland A (2009) Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol 16: Andrasik F, Grazzi L, Usai S, Kass S, Bussone G (2009) Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia [Epub ahead of print] 20. Zeeberg P, Olesen J, Jensen R (2006) Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 26: Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, Sternic N (2007) Medication overuse headache: clinical features predicting treatment outcome at 1- year follow-up. Cephalalgia 27: Andrasik F, Grazzi L, Usai S, D Amico D, Kass S, Bussone G (2007) Disability in chronic migraine with medication overuse: treatment effects at 3 years. Headache 47: Rossi R, Faroni JV, Nappi G (2008) Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 28: Hagen K, Albretsen C, Stovner LJ, Vilming S, Salvesen R, Grønning M, Helde G, Gravdahl G, Zwart JA (2009) Management of probable medication-overuse headache: 1-year randomized prospective multicenter trial. Cephalalgia 29: Bøe MG, Salvesen R, Mygland A (2009) Chronic daily headache with medication overuse: a randomized follow-up by neurologist or PCP. Cephalalgia 9: Sances G, Ghiotto N, Galli F, Guaschino E, Rezzani C, Guidetti V, Nappi G (2009) Risk factors in medication-overuse headache: a 1 year follow-up study (care II protocol). Cephalalgia (Epub) 27. Grazzi L, Andrasik F, Usai S, Bussone G (2008) In-patient vs. day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: results at one-year follow-up. Neurol Sci 29:S161 S Scher AI, Midgette LA, Lipton RB (2008) Risk factors for headache chronification. Headache 48: Diener HC, Bussone G, van Oene JC, Lahaye M, Schwalen S, Goadsby PJ (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:

Prednisone vs. placebo in withdrawal therapy following medication overuse headache

Prednisone vs. placebo in withdrawal therapy following medication overuse headache doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,

More information

Signe B Munksgaard, Lars Bendtsen and Rigmor H Jensen. Introduction. Original Article

Signe B Munksgaard, Lars Bendtsen and Rigmor H Jensen. Introduction. Original Article Original Article Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: A comparison of two consecutive treatment methods in an open-label design

More information

The validity of questionnaire-based diagnoses: the third Nord-Trøndelag Health Study

The validity of questionnaire-based diagnoses: the third Nord-Trøndelag Health Study J Headache Pain (2010) 11:67 73 DOI 10.1007/s10194-009-0174-7 ORIGINAL The validity of questionnaire-based diagnoses: the third Nord-Trøndelag Health Study 2006 2008 Knut Hagen John-Anker Zwart Anne Hege

More information

Aleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia

Aleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia European Headache School Belgrade 2012 MEDICATION OVERUSE HEADACHE Aleksandra Radojičić Headache Center, Neurology Clinic, Clinical Center of Serbia Historical data First cases were described in XVII century

More information

Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse

Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse DOI 10.1186/s40064-015-1386-8 RESEARCH Open Access Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse Fayyaz Ahmed *, Hassan

More information

Field testing of the ICHD-3β and expert opinion criteria for chronic migraine

Field testing of the ICHD-3β and expert opinion criteria for chronic migraine Jiang et al. The Journal of Headache and Pain (2016) 17:85 DOI 10.1186/s10194-016-0678-x The Journal of Headache and Pain RESEARCH ARTICLE Open Access Field testing of the ICHD-3β and expert opinion criteria

More information

Chronic migraine plus medication overuse headache: two entities or not?

Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain (2011) 12:593 601 DOI 10.1007/s10194-011-0388-3 REVIEW ARTICLE Chronic migraine plus medication overuse headache: two entities or not? Andrea Negro Paolo Martelletti Received: 7 June 2011

More information

Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headachecha_

Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headachecha_ doi:10.1111/j.1468-2982.2009.01842.x Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headachecha_1842 1149..1155 RB Grande 1,2, K Aaseth 1,3, C Lundqvist

More information

Multidisciplinary team approach to headache care

Multidisciplinary team approach to headache care Review Multidisciplinary team approach to headache care Rigmor Højland Jensen* & Annette Rasmussen Practice Points So-called refractory headache patients may be difficult to treat but are far from intractable.

More information

Treatment Of Medication. Overuse Headache

Treatment Of Medication. Overuse Headache 7 November 2012 BASH GPwSI Meeting Lecture title... Treatment Of Medication Dr... Overuse Headache Dr Marcus Lewis Dr... The National Migraine Centre International Headache Society Diagnostic criteria

More information

Study protocol: Brief intervention for medication overuse headache - A double-blinded cluster randomised parallel controlled trial in primary care

Study protocol: Brief intervention for medication overuse headache - A double-blinded cluster randomised parallel controlled trial in primary care Kristoffersen et al. BMC Neurology 2012, 12:70 STUDY PROTOCOL Open Access Study protocol: Brief intervention for medication overuse headache - A double-blinded cluster randomised parallel controlled trial

More information

Medication-overuse headache: epidemiology, diagnosis and treatment

Medication-overuse headache: epidemiology, diagnosis and treatment 522683TAW0010.1177/2042098614522683Kristoffersen and LundqvistES Kristoffersen and C Lundqvist research-article2014 Therapeutic Advances in Drug Safety Review Medication-overuse headache: epidemiology,

More information

The epidemiology of headache disorders: a face-to-face interview of participants in HUNT4

The epidemiology of headache disorders: a face-to-face interview of participants in HUNT4 Hagen et al. The Journal of Headache and Pain (2018) 19:25 https://doi.org/10.1186/s10194-018-0854-2 The Journal of Headache and Pain RESEARCH ARTICLE The epidemiology of headache disorders: a face-to-face

More information

Caspian Journal of Neurological Sciences "Caspian J Neurol Sci" Journal Homepage:

Caspian Journal of Neurological Sciences Caspian J Neurol Sci Journal Homepage: Caspian Journal of Neurological Sciences "Caspian J Neurol Sci" Journal Homepage: http://cjns.gums.ac.ir Research aper: or for Treatment of Medication Overuse Headache: A Randomized, Double- Blind Clinical

More information

OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study

OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study The Harvard community has made this article openly available. Please share how this access benefits you. Your story

More information

Medication overuse headache is a severe chronic pain condition that is preventable and treatable. An International Experience

Medication overuse headache is a severe chronic pain condition that is preventable and treatable. An International Experience Medication overuse headache is a severe chronic pain condition that is preventable and treatable An International Experience C. Tassorelli Chair of Neurolgy, Department of Brain and Behavioral Sciences,

More information

NIH Public Access Author Manuscript Curr Pain Headache Rep. Author manuscript; available in PMC 2014 May 22.

NIH Public Access Author Manuscript Curr Pain Headache Rep. Author manuscript; available in PMC 2014 May 22. NIH Public Access Author Manuscript Published in final edited form as: Curr Pain Headache Rep. 2009 December ; 13(6): 463 469. Tension-type Headache With Medication Overuse: Pathophysiology and Clinical

More information

Psychiatric Comorbidity in Transformed Migraine: Presentation, Treatment, Impact and Outcome

Psychiatric Comorbidity in Transformed Migraine: Presentation, Treatment, Impact and Outcome Jefferson Journal of Psychiatry Volume 23 Issue 1 Article 3 December 2010 Psychiatric Comorbidity in Transformed Migraine: Presentation, Treatment, Impact and Outcome Muhammad A. Abbas M.D Thomas Jefferson

More information

Treatment of withdrawal headache in patients with medication overuse headache: a pilot study

Treatment of withdrawal headache in patients with medication overuse headache: a pilot study Cevoli et al. The Journal of Headache and Pain (2017) 18:56 DOI 10.1186/s10194-017-0763-9 The Journal of Headache and Pain RESEARCH ARTICLE Open Access Treatment of withdrawal headache in patients with

More information

RESEARCH PAPER. Migraine

RESEARCH PAPER. Migraine 1 Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway 2 HØKH, Research Centre, Akershus University Hospital, Lørenskog, Norway 3 Head and Neck Research Group,

More information

Giorgio Sandrini Armando Perrotta Cristina Tassorelli Paola Torelli Filippo Brighina Grazia Sances Giuseppe Nappi

Giorgio Sandrini Armando Perrotta Cristina Tassorelli Paola Torelli Filippo Brighina Grazia Sances Giuseppe Nappi J Headache Pain (2011) 12:427 433 DOI 10.1007/s10194-011-0339-z ORIGINAL Botulinum toxin type-a in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled,

More information

Find et al. The Journal of Headache and Pain (2016) 17:20 DOI /s

Find et al. The Journal of Headache and Pain (2016) 17:20 DOI /s Find et al. The Journal of and Pain (2016) 17:20 DOI 10.1186/s10194-016-0612-2 RESEARCH ARTICLE Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics,

More information

Defining the Differences Between Episodic Migraine and Chronic Migraine

Defining the Differences Between Episodic Migraine and Chronic Migraine Curr Pain Headache Rep (2012) 16:86 92 DOI 10.1007/s11916-011-0233-z CHRONIC DAILY HEADACHE (SJ WANG, SECTION EDITOR) Defining the Differences Between Episodic Migraine and Chronic Migraine Zaza Katsarava

More information

Charly Gaul Christina van Doorn Nadine Webering Martha Dlugaj Zaza Katsarava Hans-Christoph Diener Günther Fritsche. Introduction

Charly Gaul Christina van Doorn Nadine Webering Martha Dlugaj Zaza Katsarava Hans-Christoph Diener Günther Fritsche. Introduction J Headache Pain (2011) 12:475 483 DOI 10.1007/s10194-011-0348-y ORIGINAL Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary

More information

Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine

Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine J Headache Pain (2010) 11:431 435 DOI 10.1007/s10194-010-0241-0 RAPID COMMUNICATION Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine Giovanna Gentile Marina Borro Noemi

More information

Epidemiology and Burden of Headache

Epidemiology and Burden of Headache D A N I S H H E A D A C H E C E N T E R Epidemiology and Burden of Headache EHF Headache Summer school in Belgrade Rigmor Hoejland Jensen, Professor, Dr.Med.Sci., Danish Headache Center, Department of

More information

A new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results

A new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results J Headache Pain (2004) 5:S112 S116 DOI 10.1007/s10194-004-0123-4 Michele Feleppa Fred D. Sheftell Luciana Ciannella Amedeo D Alessio Giancarlo Apice Nino N. Capobianco Donato M.T. Saracino Walter Di Iorio

More information

Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study

Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study J Headache Pain (2012) 13:521 529 DOI 10.1007/s10194-012-0469-y ORIGINAL Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study Thomas-Martin Wallasch Peter Kropp

More information

ANTIMIGRAINE MEDICINES

ANTIMIGRAINE MEDICINES 1 07.00.00.00 - ANTIMIGRAINE MEDICINES 1. Summary statement For acute migraine therapy the following new medicine is proposed: Sumatriptan 50 mg. 2. 3. Global Campaign to Reduce the Burden of Headache

More information

Prevalence of primary headaches in Germany: results of the German Headache Consortium Study

Prevalence of primary headaches in Germany: results of the German Headache Consortium Study J Headache Pain (2012) 13:215 223 DOI 10.1007/s10194-012-0425-x ORIGINAL Prevalence of primary headaches in Germany: results of the German Headache Consortium Study M-S Yoon Z. Katsarava M. Obermann G.

More information

Chronic migraine classification: current knowledge and future perspectives

Chronic migraine classification: current knowledge and future perspectives J Headache Pain (2011) 12:585 592 DOI 10.1007/s10194-011-0393-6 REVIEW ARTICLE Chronic migraine classification: current knowledge and future perspectives Gian Camillo Manzoni Vincenzo Bonavita Gennaro

More information

OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm

OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm Pedraza et al. SpringerPlus (2015) 4:176 DOI 10.1186/s40064-015-0957-z a SpringerOpen Journal RESEARCH Open Access OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with

More information

Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study

Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study Edvardsson SpringerPlus 2013, 2:479 a SpringerOpen Journal RESEARCH Open Access Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study Bengt Edvardsson Abstract Background: Chronic

More information

Risk of medication overuse headache across classes of treatments for acute migraine

Risk of medication overuse headache across classes of treatments for acute migraine Thorlund et al. The Journal of Headache and Pain (2016) 17:107 DOI 10.1186/s10194-016-0696-8 The Journal of Headache and Pain RESEARCH ARTICLE Risk of medication overuse headache across classes of treatments

More information

Medication Overuse Headache

Medication Overuse Headache Curr Neurol Neurosci Rep (2015) 15:509 DOI 10.1007/s11910-014-0509-x HEADACHE (R HALKER, SECTION EDITOR) Medication Overuse Headache Valerie Cheung & Farnaz Amoozegar & Esma Dilli Published online: 15

More information

Chronic Migraine: Epidemiology and Disease Burden

Chronic Migraine: Epidemiology and Disease Burden Curr Pain Headache Rep (2011) 15:70 78 DOI 10.1007/s11916-010-0157-z Chronic Migraine: Epidemiology and Disease Burden Aubrey N. Manack & Dawn C. Buse & Richard B. Lipton Published online: 10 November

More information

An Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California

An Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California An Overview of MOH IHS ASIAN HA MASTERS SCHOOL MARCH 24, 2013 ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California President-Elect

More information

Al Jumah et al. The Journal of Headache and Pain 2013, 14:16

Al Jumah et al. The Journal of Headache and Pain 2013, 14:16 Al Jumah et al. The Journal of Headache and Pain 2013, 14:16 RESEARCH ARTICLE Open Access HURT (Headache Under-Response to Treatment) questionnaire in the management of primary headache disorders: reliability,

More information

From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries

From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries J Headache Pain (2009) 10:71 76 DOI 10.1007/s10194-009-0101-y REVIEW ARTICLE From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries

More information

Classification of headaches

Classification of headaches Classification of headaches Jasna Zidverc Trajković Headache center Headache in adults: 1-year prevalence 13.4 Kryst 35.9 Miranda 28.7 Jaillard 87.3 O Brien 63.1 Wiehe 37.3 Lavados 59.7 Schwartz 76.0 Boardman

More information

Decision-making deficit in chronic migraine patients with medication overuse

Decision-making deficit in chronic migraine patients with medication overuse DOI 10.1007/s10072-012-1071-4 ORAL COMMUNICATIONS Decision-making deficit in chronic migraine patients with medication overuse B. Biagianti L. Grazzi O. Gambini S. Usai R. Muffatti S. Scarone G. Bussone

More information

Update on Medication-Overuse Headache and Its Treatment Maria Adele Giamberardino, MD 1 Dimos-Dimitrios Mitsikostas, MD 2 Paolo Martelletti, MD 3,*

Update on Medication-Overuse Headache and Its Treatment Maria Adele Giamberardino, MD 1 Dimos-Dimitrios Mitsikostas, MD 2 Paolo Martelletti, MD 3,* 73: 71) 5102( Curr Treat Options Neurol DOI 10.1007/s11940-015-0368-z Headache (JR Couch, Section Editor) Update on Medication-Overuse Headache and Its Treatment Maria Adele Giamberardino, MD 1 Dimos-Dimitrios

More information

Management of headache

Management of headache Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,

More information

Guidelines for controlled trials of drugs in tension-type headache: Second edition

Guidelines for controlled trials of drugs in tension-type headache: Second edition Guidelines Guidelines for controlled trials of drugs in tension-type headache: Second edition Cephalalgia 30(1) 1 16! International Headache Society 2009 Reprints and permissions: sagepub.co.uk/journalspermissions.nav

More information

Tension-type headache Comorbidities EHF-summerschool Belgrade May 2012

Tension-type headache Comorbidities EHF-summerschool Belgrade May 2012 Tension-type headache Comorbidities EHF-summerschool Belgrade May 2012 Conflicts of Interest: Lectures for Pfizer, Berlin-Chemie, Allergan, Merck Member of advisory boards in: ATI, Medotech, Neurocore,

More information

High dietary caffeine consumption is associated with a modest increase in headache prevalence: results from the Head-HUNT Study

High dietary caffeine consumption is associated with a modest increase in headache prevalence: results from the Head-HUNT Study J Headache Pain (2009) 10:153 159 DOI 10.1007/s10194-009-0114-6 ORIGINAL High dietary caffeine consumption is associated with a modest increase in headache prevalence: results from the Head-HUNT Study

More information

Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example

Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example J Headache Pain (2006) 7:27 33 DOI 10.1007/s10194-006-0266-6 ORIGINAL Julio Pascual Hans-Christoph Diener Hélène Massiou Value of postmarketing surveillance studies in achieving a complete picture of antimigraine

More information

A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience

A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience Negro et al. The Journal of Headache and Pain (2016) 17:1 DOI 10.1186/s10194-016-0591-3 RESEARCH ARTICLE A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache:

More information

Prevalence of headache in an elderly population: attack frequency, disability, and use of medication

Prevalence of headache in an elderly population: attack frequency, disability, and use of medication J Neurol Neurosurg Psychiatry 2001;70:377 381 377 Department of Neurological Sciences, La Sapienza University, Via dell Amba Aradam 21, 00184 Rome Rome, Italy M Prencipe A R Casini C Ferretti M Santini

More information

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version www.pdflib.com sales@pdflib.com Headache 2008 the Authors Journal compilation 2008 American Headache Society

More information

Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study

Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study Cephalalgia OnlineFirst, published on May 17, 2010 as doi:10.1177/0333102410372427 Original Article Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study

More information

MIGRAINE ASSOCIATION OF IRELAND

MIGRAINE ASSOCIATION OF IRELAND MIGRAINE ASSOCIATION OF IRELAND HEADACHE IN MEN: THE FACTS This leaflet was composed by Paolo Rossi M.D., Ph.D. of the European Headache Alliance to mark European Migraine Day of Action 2014. Why a leaflet

More information

Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache

Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache J Headache Pain (2011) 12:511 519 DOI 10.1007/s10194-011-0364-y REVIEW ARTICLE Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache Charly Gaul

More information

Determining the Disability Levels of Women with Migraines in their Daily Life Activities

Determining the Disability Levels of Women with Migraines in their Daily Life Activities International Journal of Caring Sciences May August 2017 Volume 10 Issue 2 997 Original Article Determining the Disability Levels of Women with Migraines in their Daily Life Activities Nuray Dayapogu,

More information

New daily persistent headache: Should migrainous features be incorporated?

New daily persistent headache: Should migrainous features be incorporated? Original Article New daily persistent headache: Should migrainous features be incorporated? Cephalalgia 31(15) 1561 1569! International Headache Society 2011 Reprints and permissions: sagepub.co.uk/journalspermissions.nav

More information

RISK FACTORS AND PROGNOSIS OF CHRONIC MIGRAINE

RISK FACTORS AND PROGNOSIS OF CHRONIC MIGRAINE RISK FACTORS AND PROGNOSIS OF CHRONIC MIGRAINE Gretchen E. Tietjen, MD University of Toledo Toledo, Ohio Learning objectives At the conclusion of this presentation, participants should be able to: 1. Understand

More information

Opioids can be useful in the treatment of headache

Opioids can be useful in the treatment of headache Neurol Sci (2013) 34 (Suppl 1):S119 S124 DOI 10.1007/s10072-013-1416-7 CONTROVERSIES Opioids can be useful in the treatment of headache Cinzia Finocchi Erica Viani Ó Springer-Verlag Italia 2013 Abstract

More information

Chronic daily headache (CDH), defined

Chronic daily headache (CDH), defined FINDING A FIT: STRATEGIES FOR CHRONIC MIGRAINE PROPHYLAXIS David W. Dodick, MD, FRCP(C), FACP ABSTRACT Chronic daily headache (CDH) affects approximately 4% to 5% of the population and is responsible for

More information

Clinical Characteristics of Chronic Daily Headache Patients Visit to University Hospital

Clinical Characteristics of Chronic Daily Headache Patients Visit to University Hospital Clinical Characteristics of Chronic Daily Headache Patients Visit to University Hospital Jin-Kuk Do, M.D., Hee-Jong Oh, M.D., Dong-Kuck Lee, M.D. Department of Neurology, Taegu Hyosung Catholic University

More information

Prevalence and disability of headache among Norwegian adolescents: A cross-sectional school-based study

Prevalence and disability of headache among Norwegian adolescents: A cross-sectional school-based study Original Article Prevalence and disability of headache among Norwegian adolescents: A cross-sectional school-based study Cephalalgia ()! International Headache Society 25 Reprints and permissions: sagepub.co.uk/journalspermissions.nav

More information

Risk Factors for Chronic Daily Headache

Risk Factors for Chronic Daily Headache Risk Factors for Chronic Daily Headache Ann I. Scher, PhD, Richard B. Lipton, MD, and Walter Stewart, PhD Address Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, 7201

More information

Migraine Disability Awareness Campaign in Asia: Migraine Assessment for Prophylaxis

Migraine Disability Awareness Campaign in Asia: Migraine Assessment for Prophylaxis Headache 2008 the Authors Journal compilation 2008 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2008.01088.x Published by Wiley Periodicals, Inc. Research Submission Migraine Disability

More information

Physiotherapy for tension-type headache: a controlled study

Physiotherapy for tension-type headache: a controlled study Blackwell Science, LtdOxford, UKCHACephalalgia1468-2982Blackwell Science, 232412936Original ArticlePhysiotherapy for tension-type headachep Torelli et al. Physiotherapy for tension-type headache: a controlled

More information

Research Submission. Accepted for publication December 14, 2004.

Research Submission. Accepted for publication December 14, 2004. Research Submission Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double-Blind, Placebo-Controlled

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle  holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/29646 holds various files of this Leiden University dissertation. Author: Dekker, François (Frans) Title: Patients preference in migraine Issue Date: 2014-11-05

More information

National Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)

National Institute for Health and Clinical Excellence. Single Technology Appraisal (STA) National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

More information

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache Measure Description Percentage of patients age 18 years old and older with a diagnosis of primary headache

More information

Botulinum toxin type A is currently being

Botulinum toxin type A is currently being EMERGING PREVENTIVE OPTIONS FOR CHRONIC DAILY HEADACHE * David W. Dodick, MD, FRCP(C), FACP ABSTRACT Approximately 3% to 5% of the population is affected by headaches on a daily or almost daily basis.

More information

Recognition and treatment of medication overuse headache

Recognition and treatment of medication overuse headache Recognition and treatment of medication overuse headache Marcus Lewis MA, MRCGP, DRCOG, DFSRH 20 Mean weekly headache index 15 10 5 Medication overuse headache is a common condition responsible for a high

More information

David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA

David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA Headache Masters School 2013 in Asia Sunday March 24, 2013 Procedural Medicine Workshop Onabotulinumtoxin A: Evidence, Injection Technique, and Mechanism of Action David W. Dodick M.D. Professor Director

More information

Specific Objectives A. Topics to be lectured and discussed at the plenary sessions

Specific Objectives A. Topics to be lectured and discussed at the plenary sessions Specific Objectives A. Topics to be lectured and discussed at the plenary sessions 0. Introduction: Good morning ICHD-III! Let s start at the very beginning. When you read you begin with A-B-C, so when

More information

Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches

Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches Neurol Sci (2017) 38:999 1007 DOI 10.1007/s10072-017-2888-7 ORIGINAL ARTICLE Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches Veronica Villani 1

More information

Guidelines for the organization of headache education in Europe: the headache school II

Guidelines for the organization of headache education in Europe: the headache school II J Headache Pain (2010) 11:161 165 DOI 10.1007/s10194-010-0195-2 TUTORIAL Guidelines for the organization of headache education in Europe: the headache school II Rigmor Jensen Dimos D. Mitsikostas Dominique

More information

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen

More information

Hans-Christoph Diener 1*, Morris Gold 2 and Martina Hagen 3

Hans-Christoph Diener 1*, Morris Gold 2 and Martina Hagen 3 Diener et al. The Journal of Headache and Pain 2014, 15:76 RESEARCH ARTICLE Open Access Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone

More information

Migraine attacks in the pharmacy: a survey in Piedmont, Italy

Migraine attacks in the pharmacy: a survey in Piedmont, Italy DOI 10.1007/s10072-014-1733-5 FICEF SYMPOSIUM - HEADACHE IN THE FRONT LINE: FROM PHARMACIST TO GENERAL PRACTITIONER Migraine attacks in the pharmacy: a survey in Piedmont, Italy P. Brusa G. Allais G. Bussone

More information

An Expert System for Headache Diagnosis: The Computerized Headache Assessment Tool (CHAT) Morris Maizels, MD; William J.

An Expert System for Headache Diagnosis: The Computerized Headache Assessment Tool (CHAT) Morris Maizels, MD; William J. Headache 2007 the Authors Journal compilation 2008 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2007.00918.x Published by Blackwell Publishing Research Submission An Expert System

More information

Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan

Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan J Headache Pain (2012) 13:311 319 DOI 10.1007/s10194-012-0447-4 ORIGINAL Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan Yong-Chen Chen Chao-Hsiun Tang Kwong Ng Shuu-Jiun

More information

Despite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability

Despite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for

More information

Incidence and Risk Factors of Chronic Daily Headache in Young Adolescents: A School Cohort Study

Incidence and Risk Factors of Chronic Daily Headache in Young Adolescents: A School Cohort Study ARTICLE Incidence and Risk Factors of Chronic Daily Headache in Young Adolescents: A School Cohort Study AUTHORS: Shiang-Ru Lu, MD, a Jong-Ling Fuh, MD, b,c,d Shuu- Jiun Wang, MD, b,c,d Kai-Dih Juang,

More information

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical

More information

2 nd Resubmission. 13 January 2017

2 nd Resubmission. 13 January 2017 2 nd Resubmission botulinum toxin A, 50 Allergan units, 100 Allergan units, 200 Allergan units, powder for solution for injection (Botox ) SMC No. (692/11) Allergan Limited 13 January 2017 The Scottish

More information

Recommendations for headache service organisation and delivery in Europe

Recommendations for headache service organisation and delivery in Europe J Headache Pain (2011) 12:419 426 DOI 10.1007/s10194-011-0320-x ORIGINAL Recommendations for headache service organisation and delivery in Europe T. J. Steiner F. Antonaci R. Jensen M. J. A. Lainez M.

More information

Research Article Prevalence of Chronic Headache in Croatia

Research Article Prevalence of Chronic Headache in Croatia BioMed Research International Volume 2013, Article ID 837613, 5 pages http://dx.doi.org/10.1155/2013/837613 Research Article Prevalence of Chronic Headache in Croatia Vlasta VukoviT-CvetkoviT, 1 Davor

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates September 2017 By Lindsay Slowiczek, PharmD Migraines are often considered to be a condition affecting younger or middle-aged patients, during which patients experience episodic,

More information

One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults

One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults J Headache Pain (2012) 13:147 157 DOI 10.1007/s10194-011-0414-5 ORIGINAL One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults Mustafa

More information

Sleep Quality and Depression among Patients with Migraine

Sleep Quality and Depression among Patients with Migraine ORIGINAL REPORT Sleep Quality and Depression among Migraine Khosro Sadeghniiat 1, Alaleh Rajabzadeh 2, Mahsa Ghajarzadeh 3, and Majid Ghafarpour 1 Center for Research on Occupational Diseases, Tehran University

More information

The paradoxical effects of analgesics and the development of chronic migraine

The paradoxical effects of analgesics and the development of chronic migraine View and review Arq Neuropsiquiatr 2011;69(3):544-551 The paradoxical effects of analgesics and the development of chronic migraine Marcelo E. ABSTRACT In a subgroup of individuals episodic migraine evolves

More information

The Journal of Headache and Pain

The Journal of Headache and Pain Grazzi et al. The Journal of Headache and Pain (2017) 18:15 DOI 10.1186/s10194-017-0728-z The Journal of Headache and Pain RESEARCH ARTICLE Open Access Mindfulness and pharmacological prophylaxis after

More information

The use of combination therapies in the acute management of migraine

The use of combination therapies in the acute management of migraine REVIEW The use of combination therapies in the acute management of migraine Abouch Valenty Krymchantowski Headache Center of Rio, Rio de Janeiro, Brazil; Outpatient Headache Unit of the Instituto de Neurologia

More information

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA Preventive treatment of migraine Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA No disclosures Disclosures Many preventive treatments for migraine are not FDA-approved

More information

Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation

Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation Mitsikostas, Dimos D.; Edvinsson, Lars; Jensen, Rigmor H.; Katsarava, Zaza; Lampl,

More information

medications. This was an openlabel study consisting of patients with migraines who historically failed to respond to oral triptan

medications. This was an openlabel study consisting of patients with migraines who historically failed to respond to oral triptan J Headache Pain (2007) 8:13 18 DOI 10.1007/s10194-007-0354-7 ORIGINAL Seymour Diamond Fred G. Freitag Alexander Feoktistov George Nissan Sumatriptan 6 mg subcutaneous as an effective migraine treatment

More information

Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders

Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders J Headache Pain (2012) 13:53 59 DOI 10.1007/s10194-011-0395-4 ORIGINAL Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders Abouch Valenty Krymchantowski

More information

The validity of recognition-based headache diagnoses in adolescents. Data from the Nord-Trøndelag Health Study , Head-HUNT-Youth

The validity of recognition-based headache diagnoses in adolescents. Data from the Nord-Trøndelag Health Study , Head-HUNT-Youth Blackwell Science, LtdOxford, UKCHACephalalgia0333-1024Blackwell Science, 200323Original Article Recognition-based headache diagnoses in adolescentsj-a Zwart et al. The validity of recognition-based headache

More information

Mild Head Trauma and Chronic Headaches in Returning US Soldiers. Brett J. Theeler, MD; Jay C. Erickson, MD, PhD

Mild Head Trauma and Chronic Headaches in Returning US Soldiers. Brett J. Theeler, MD; Jay C. Erickson, MD, PhD Headache 2009 the Authors Journal compilation 2009 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2009.01345.x Published by Wiley Periodicals, Inc. Research Submission Mild Head Trauma

More information

Predictors of treatment outcome in headache patients with the Millon Clinical Multiaxial Inventory III (MCMI-III)

Predictors of treatment outcome in headache patients with the Millon Clinical Multiaxial Inventory III (MCMI-III) J Headache Pain (2007) 8:28 34 DOI 10.1007/s10194-007-0358-y ORIGINAL Jacob Sander Hansen Lars Bendtsen Rigmor Jensen Predictors of treatment outcome in headache patients with the Millon Clinical Multiaxial

More information

What is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old?

What is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 What is the Effectiveness of OnabotulinumtoxinA

More information

Comprehensive Application of the International Classification of Headache Disorders Third Edition, Beta Version

Comprehensive Application of the International Classification of Headache Disorders Third Edition, Beta Version ORIGINAL ARTICLE Neuroscience http://dx.doi.org/10.3346/jkms.2016.31.1.106 J Korean Med Sci 2016; 31: 106-113 Comprehensive Application of the International Classification of Headache Disorders Third Edition,

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority Quality ID #435: Quality of Life Assessment For Patients With Primary Headache Disorders National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Patient Reported Functional Outcomes

More information